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A utoimmune diseases probably have a multi- tude of causes. It is obvious that exogenous agents, particularly drugs, may trigger the de- velopment of autoimmune responses leading 
to bullous eruptions. In the literature several cases of 
drug-induced (disseminated) bullous pemphigoid (BP) 
have been reported (see article by Fellner in this issue); 
however, localized variants of pemphigoid and acquired 
epidermolysis bullosa, although to a lesser extent, appar- 
ently can also be induced by drugs. 
Important localized variants of pemphigoid are cicatri- 
cial pemphigoid (Cl’) (synonyms: mucous membrane 
pemphigoid [MMP], ocular pemphigoid) and two non- 
mucosal localized variants: the non-mucosal scarring 
type pemphigoid (Brunsting-Perry type) and the non- 
scarring localized-type pemphigoid (LBP). 
Cicatricial pemphigoid is a rather rare disease of late 
middle age that occurs particularly on the mucous mem- 
branes of the eyes, oropharynx, genitalia, or anus. The 
characteristic skin picture is that of localized recurrent 
blisters with the development of scarring.’ The cicatricial 
process can cause serious adhesions, strictures, and de- 
pending on the localization, on the long-term loss of 
function. Histologically, in contrast to BP, eosinophils in 
LBP and CP are usually present in significantly small 
numbers. Particularly in Cl’ lesions, a fairly dense, some- 
times predominant lymphocytic inflammatory infiltrate 
is observed in the dermis. 
Immunofluorescence (IF) studies in CP show a linear 
deposition of IgG and complement along the basement 
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membrane of lesional and perilesional skin, but circulat- 
ing serum autoantibodies with affinity for the basement 
membrane are detectable in only a minority of the pa- 
tients.2 
Several authors have reported cases classified as CP or 
MMP, apparently triggered by drugs3-” (Table 1). Two 
cases of drug-induced CP3,‘j are discussed here in more 
detail. 
Case Report 1 
A man, aged 46 years, who had been treated long-term 
with practolol (Eraldin) (daily oral dose 600 mg) for an- 
gina developed, after 2.5 years of usage, a chronic bilat- 
eral inflammatory blistering eruption on the ocular 
mucous membranes of the eyes leading to fibrosis and 
cicatrization with histologic and immunologic features 
compatible with CP (Figure 1). Small papules and vesicles 
were observed in infiltrated erythematous areas on the 
conjunctivae together with focal scarring and shrinkage. 
At that time, the patient also had a psoriasiform rash 
localized on the chest and the extremities. Five weeks 
after stopping practolol no new active lesions on the con- 
junctivae were noted, but the old lesions remained unre- 
solved. Epicutaneous and intracutaneous skin tests with 
practolol at that time (1975) were negative. 
Histopathologic examination of the lesional ocular 
mucous membrane adjacent to a blister showed subepi- 
thelial cleavage at the basement membrane. An infiltrate 
composed largely of lymphocytes with some eosinophils 
and plasmacytes and a large number of dilated blood 
vessels was observed in the submucosa. 
Immunofluorescence studies on sections of the le- 
sional mucosa adjacent to a blister showed a linear band- 
like fluorescence in the subepithelial regions with anti- 
sera against IgG and complement, but because of tissue 
degeneration of the epithelium at these sites, the inter- 
pretation of the staining was less significant for a definite 
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Table 1. Data in the Literature on Drug-Induced Cicatricial Pemphigoid”: Localization of the 
Lesions and Systemic or Topical Drugs Considered to Be Responsible for Eliciting the Syndrome 
Authors Nt 
Van Joost et al3 
Pattern et al’ 
Pegum and Pembroke5 
Van Joost et al6 
Hirst et al7 
Shuttleworth and 
Graham-Browns 
Harrington and 
Messenger9 
1 
2 
1 
1 
2 
I 
Oral indomethacin (2) 2 Positive Oral and cutaneous (1) 
Ocular, oral, and 
cutaneous (1) 
5 Negative Ocular (5) Topical glaucoma 
medication (5) 
1 Negative Ocular** Oral sulfadoxine 
IFS 
Positive 
§ 
Localization 
Ocular 
Ocular (2)7 
W) Ocular and oral 
Positive Vulval, anal, and perianal 
km Ocular (2) 
Positive Ocular, oral, cutaneous 
Drug Responsible 
Oral practolol 
Topical echothiophate 
iodide (2) 
Oral o-penicillamine 
Oral clonidine 
Topical pilocarpine (1) 
Topical demecarium 
Bromide (1) 
Oral o-penicillamine 
Fiore et al”’ 
Thiel et al” 
l Synonyms: BMM, ocular pemghigoid. 
t N = number ofpatients classified as drug-induced cicatricial pemphigoid, as drug-induced mucous membranepemphigoid, 
or as drug-induced ocular pemphigoid. In some of the cases a definite clinical cicatrization was observed. 
$ IF = immunofluorescence examination of the skin. 
6 IF not done or not available. 
1 Number of patients in parentheses. 
” This patient also had erythema exudativum multiforme lesions of other mucous membranes and of the skin. 
classification. A conspicuous linear deposition of IgG and tinuclear antibodies in the absence of anti-DNA antibod- 
complement, however, was observed along the basement ies. Intercellular pemphigoid-like antibodies (titer 1: 40) 
membrane of the buccal mucous membrane. There were were also detected using guinea pig lip as the substrate, 
no clinical signs of CP at this site. but 2 months after stopping the practolol treatment, these 
On IF examination, the serum samples did not contain autoantibodies had disappeared.3 Practolol was with- 
basement membrane autoantibodies, but did contain an- drawn from the market in 1975 because of a high inci- 
Figure 1. Drug-induced cicatricial pemphigoid of the ocular mucous membrane 
caused by oral practolol (Eraldin). 
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Figure 2. Drug-induced cicatricial pemphigoid of the anal 
and perianal regions caused by clonidine (Catapresan). 
dence of serious side effects on the skin and several other 
organs, including sclerosing peritonitis. 
Case Report 2 
A woman, aged 59 years, treated for systemic hyperten- 
sion with clonidine (Catapresan) (daily oral dose two or 
three O-250-mg capsules) for 2 years, developed a blister- 
ing cicatricial eruption with primary localization on the 
mucosal surfaces of the vulva and the anus with perianal 
extension (Figure 2). 
Furthermore, ocular mucosal alterations classified as 
“ocular pemphigoid” have been reported to result from 
various topical treatments (see Table 1). In none of five 
patients with ocular pemphigoid induced by topical glau- 
coma medications were linear immunoglobulin and/or 
complement deposition along the basement membrane of 
lesional skin observed using IF techniques.‘O In four pa- 
tients, the lesions were self-limiting and nonprogressive 
after stopping the topical treatment. One patient, how- 
ever, developed progressive scarring even though the of- 
fending medication had been discontinued. Because the 
IF examination was negative it is uncertain whether these 
cases represent true CP. The term cicatricial pemphigoid- 
like or ocular pemphigoid-like drug reaction is probably 
more appropriate on clinical and histologic grounds. 
Histopathologic examination of the perilesional skin Of interest is a detailed report on a patient who devel- 
adjacent to a blister on perianal skin showed subepider- oped exudative erythema multiforme major with massive 
ma1 blister formation at the basement membrane (Figure involvement of the skin, oral mucous membranes, and 
3). A cellular infiltrate consisting predominantly of lym- mucous membranes of both eyes as a result of sulfadox- 
phocytes and neutrophils and, to a lesser extent, eosino- ine, present as one of the constituents in the antimalaria 
phils was seen diffusely in the upper dermis and around drug Fansidar (sulfadoxine and pyrimethamine).” The 
the blood vessels. No clear fibrosis of dermal tissue was chronic inflammation of the eyes led to proliferation in 
observed in the biopsy that was examined. the conjunctivae. The final clinical picture was compara- 
Immunofluorescence studies on sections of perianal 
skin adjacent to the blister formation showed predomi- 
nantly a linear deposition of IgG and complement along 
the basement membrane (Fig 4). Basement membrane 
autoantibodies were not detected in the serum. 
Reappearance of skin lesions localized at the anal and 
perianal regions, this time accompanied by erythematous 
nonblistering eruptions on the breast, and abdomen, after 
reexposure to clonidine was highly suggestive of a rela- 
tionship between the drug and the development of a syn- 
drome that was classified as CP.6 
In addition to the cardiovascular drugs implicated in 
these two cases of CP, nonsteroidal anti-inflammatory 
drugs (NSAIDs) and n-penicillamine have also been im- 
plicated in the development of Cl’. 
Two cases classified as MMP were apparently induced 
by a NSAID.9 Both patients had received indomethacin 
for rheumatoid arthritis. MMP developed in both patients 
6 and 8 weeks respectively after treatment with this drug. 
In the same report, the authors stated that in a retrospec- 
tive study it appeared that five other patients with MMP 
observed previously had all taken NSAIDs in the 6 
months prior to the onset of the skin lesions. 
Patients with rheumatoid arthritis who developed CP 
after the introduction of n-penicillamine (D-/Q&li- 
methyl cysteine) have been reported5,* (see Table 1). Al- 
though a direct link between the two conditions (CP and 
rheumatoid arthritis) may exist independently of the use 
of drugs, the possibility that CP was a complication of 
n-penicillamine treatment was considered more 1ikely.a 
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Figure 3. Subevidermal blister formation in drug-induced (clonidine) cicatricial pemphigoid 
(Hi, X250). ’ 
ble to that of severe (ocular) CP, including the develop- 
ment of scarring and blindness in both eyes. 
Discussion 
Drug-induced MMP, particularly in the eyes, may be 
thought of as a spectrum of diseases. It may occur as a 
localized, nonprogressive, “toxic” reaction that remains 
self-limited once the offending topical medication is 
withdrawn; or it can progress relentlessly with scarring 
having the characteristic immunologic (IF) features of 
true CP; or it can occur as a concomitant manifestation of 
other syndromes such as exudative erythema multi- 
forme.lO~ll 
In the two cases of drug-induced Cl’ described here, 
the underlying pathomechanisms of the side effects re- 
mained unelucidated. A previous study indicated that 
during long-term topical ocular treatment with P-adre- 
nergic receptor blocking agents, sensitization can occur as 
a result of delayed-type hypersensitivity.12 Interaction of 
/I-adrenergic receptor blocking agents (practolol) or 
a+adrenergic receptor stimulating agents (clonidine) with 
the cyclic AMP system in the epidermal (mucosal epi- 
thelial) cells may be operative. In view of the concept 
that at least a part of the basement membrane is of epi- 
dermal origin, it is tempting to assume that the underlying 
factors involved in these cases of drug-induced Cl’ are 
related to local metabolic disturbances (cyclic AMP sys- 
tem?) in the germinal cells. This could lead to the deposi- 
tion of immunogens in the basement membrane and may 
subsequently lead to the induction of cellular immunity 
and/or to the formation of autoantibodies and of im- 
munecomplexes in situ. Other drugs might also play a 
role in such metabolic disturbances. In this respect, it is 
interesting that serum autoantibodies with affinity for the 
cytoplasm of epithelial basal cells have been observed in 
patients on different drugs and with different clinical ad- 
verse effects (eg, exudative erythema multiforme and 
vasculitis).13*14 
Another possible explanation for the elicitation of au- 
toantibodies comes from the experience that prostaglan- 
dins of the E series inhibit the expression of major histo- 
compatibility class II antigens (Ia antigens) by murine 
macrophages and human Langerhans cells.15 Drugs like 
indomethacin (see Table l), that inhibit prostaglandin 
synthesis have been shown to increase the expression of 
Ia antigens by these cells, mimicking the action of Ia-in- 
ducing lymphokines such as gamma interferon. It has 
been suggested that increased Ia expression enhances 
humoral immune responses.16 Thus, indomethacin and 
other cyclooxygenase inhibitors might exacerbate au- 
toimmune disease through such mechanisms. 
Drugs may have alternating effects on both the hu- 
moral and the cellular limbs of the autoimmune response. 
A mononuclear inflammatory infiltrate may be present in 
the skin lesions of (disseminated) bullous pemphigoid 
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Figure 4. lmmunofluorescence study. Border of a 
subepidermal blister. Predominantly linear fluorescence (IgG/ 
FlTC staining) along the basement membrane in drug-induced 
(clonidine) cicatricial pemphigoid 0<500). 
(BP), but usually mononuclear infiltrates are predomi- 
nant in the lesions of the chronic localized variants of the 
disease (Cl’ and LBP). This observation may favor a pos- 
sible role of T cell-mediated immunity in terms of anti- 
gen-processing (including immunogens precipitated by 
drugs) in the early events of this disease complex and 
probably also in the perpetuation of the disease.17,18 
Important observations have been reported in active 
BP in favor of “in situ” presentation of antigens located in 
the basement membrane to T cells.“,19 A redistribution of 
Langerhans cells toward the basement membrane and an 
increase in the total number of Langerhans cells in the 
lesional skin have been observed.” Furthermore, in BP 
significantly increased numbers of helper-T cells and of 
HLA-DR-positive T cells in the peripheral blood were 
observed.‘* These data may suggest that helper-T cell 
activation may be involved in the acute phase of the dis- 
ease.16 In addition, in BP, a decreased level of interleukin- 
2 (IL-2), assumed to be caused by the consumption of 
IL-2, has been reported. l9 Thus, T cell-mediated reactions 
may be an important link in the inductive phase of im- 
munity leading finally to subepidermal bullous autoim- 
mune disorders. Particularly in BP, the formation of 
“antigen (BM) - antibody - complement complexes” is 
thought to play a key role in the chemotaxis of eosino- 
philic granulocytes and in blister formation.20 Tissue in- 
jury based on circulating autoantibodies may be under- 
stood better in cases of BP than in the localized chronic 
variants of the disease (LBP and CP). 
In LBP, the predominance of activated helper/inducer 
T cells in the dermoepidermal regions as well as the ex- 
pression of IL-2 receptor (IL-2R) on eosinophils in the 
dermal infiltrate have been observed.21 IL-2R can be ex- 
pressed not only by T cells, but apparently also by non- 
lymphoid cells. Subsets of activated T cells may possibly 
produce precursors of eosinophils. This may favor anti- 
gen processing at the local level, leading to T cell-me- 
diated recruitment of eosinophils.21 LBP resembling fixed 
drug eruption has been reported.22 Processes mediated by 
T cells similar to those described earlier might also play a 
role in the different drug-induced variants of pemphi- 
goid, particularly in drug-induced CP. Future studies are 
required to establish the exact role of T cells in drug-in- 
duced pemphigoid variants. In the case reviewed earlier 
in this chapter in which drug-induced CP developed to- 
gether with exudative erythema multiforme lesions, the 
lymphocyte transformation test with the drug considered 
as responsible (sulfadoxine) remained positive at least 18 
months after the onset of the disease.” 
Drug-Induced Acquired Epidermolysis Bullosa 
Important clinical criteria for acquired epidermolysis bul- 
losa (AEB) are trauma-induced blisters occurring over the 
joints of the hands, feet, and elbows; additional atrophic 
scars; milia; and nail dystrophy. There is no family history 
and there is postinfancy onset of the disease. On the 
ultrastructural level the blister formation occurs beneath 
the basal lamina, with a zone of amorphous material be- 
neath the basal lamina remaining on the epidermal side of 
the blister.23 
Apart from neutrophils, a mild chronic inflammatory 
(lymphohistiocytic) perivascular infiltrate may be present 
in the lesions. In the majority of cases, the immunoreac- 
tants in the basement membrane are of the IgG class, but 
IgM, IgA, and complement deposition at this region may 
also be present in some patients.” Circulating IgG anti- 
bodies against the basement membrane are usually not 
detectable in the serum. There is some evidence that AEB 
is in linkage disequilibrium with the MHC class II allele 
HLA-DR 2.25 The immune cascade in AEB has yet to be 
elucidated, but in the inflammatory variant of the disease, 
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neutrophils are suspected to play an important role in 
tissue injury.24 
The results of previous studies at the ultrastructural 
level indicate that IgG depositions in both BP and CP are 
located in the lamina lucida or the lamina basale.24*26 In 
AEB, the ultrastructural location of immunoglobulins has 
been observed to occur just beneath the lamina densa,23J6 
which does not support the hypothesis that AEB may be a 
variant of pemphigoid. *’ Drug-induced skin eruptions 
classified as AEB-like disease have been described appar- 
ently as a result of sulfonamides,** sulfamethoxypyrida- 
zine 29 o-penicillamine,30-32 and furosemide33; however, 
in mbst of these reports the definite proof for this classifi- 
cation was lacking. 
Furosemide, in high doses, is used extensively to treat 
edematous patients with chronic renal failure. Seven 
patients developed a skin syndrome classified as AEB 
while on high-dose furosemide treatment.33 These cases 
are described here in more detail. Of the seven pa- 
tients (five men and two women, aged 17 to 57 years), 
three had glomerulonephritis; the other diagnoses were 
pyelonephritis, polycystic disease, secondary amyloido- 
sis, and polyarthritis nodosa. Renal function was seri- 
ously impaired in six patients (creatinine clearance 4- 
10 mL/min) and the remaining patient had refractory 
edema associated with the nephrotic syndrome. The dose 
of furosemide ranged from 0.5 to 2.0 g/day and most 
patients had received a high dose of this drug for several 
months before the skin lesions appeared. The shortest 
duration of treatment was 2 months and the longest, 3 
years. Superficial bullae, up to 3 cm in diameter, were 
situated on the dorsum of the fingers or hands and, in two 
patients, also on the dorsum of the feet. The lesions were 
itchy, but without systemic manifestations. The bullae 
were superficial, leaving a raw surface, and filled with 
clear fluid. Minor trauma had predisposed to the devel- 
opment of the bullae. Porphyrin studies on urine, feces, 
and blood were carried out in three patients. The results 
were negative in all three cases. Skin biopsy showed a 
subepidermal blister with very few inflammatory cells in 
the blister fluid and minimal inflammatory infiltrate in 
the dermis. The condition appeared clinically and histo- 
logically to be AEB. The lesions persisted for 3 to 9 
weeks and then healed, whether or not furosemide was 
continued.33 
Discussion 
Dermatologic complications attributed to the use of furo- 
semide are rare. Furosemide as the cause of drug-induced 
bullous pemphigoid (BP) has also been reported.34*35 The 
mechanism of blistering in drug-induced AEB-like skin 
eruptions is obscure. Although its onset in relation to 
high-dose furosemide is extremely suggestive, the blis- 
tering tendency subsides in weeks or months, whether or 
not large doses of furosemide are continued. An impor- 
tant primer role for immunologic mechanisms seems to be 
unlikely in the cases described. It is tempting to specu- 
late that the drug, particularly at high doses, interferes 
with tissue metabolism in the dermoepidermal region 
in a manner that depends on light exposure, inducing 
what is clinically an acquired form of epidermolysis bul- 
losa. 
Conclusions 
It can be concluded that both cicatricial pemphigoid and 
acquired epidermolysis bullosa, or patterns closely mim- 
icking these syndromes, may be triggered by the use of 
certain drugs. Ocular treatment with topical drugs can 
lead to a syndrome that clinically resembles ocular pem- 
phigoid; however, the results of immunofluorescence 
studies on the tissue in a number of cases reported in the 
literature and reviewed in this article were either negative 
or not available (see Table 1). Therefore, a definite classi- 
fication cannot be established. Moreover, we think that in 
the majority of cases with lesions induced by topical 
drugs, the term ocular pemphigoid cannot be considered 
an appropriate synonym for cicatricial pemphigoid be- 
cause fibrosis and cicatricial lesions are absent. 
Systemic treatment with certain drugs more evidently 
may trigger a syndrome compatible with true cicaticial 
pemphigoid in which, besides the mucosal membranes, 
the skin may also be involved (see Table 1). 
Further studies on the interference of drugs with tissue 
metabolism in the skin and on the aberrant immune 
responses in cicatricial pemphigoid and acquired epi- 
dermolysis bullosa will cast more light on the role of 
drugs in the pathomechanisms of these blistering dis- 
orders. 
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